Genesis Molecular AI
Bay Area AI small-molecule company (formerly Genesis Therapeutics); Pearl structure model, Incyte/Gilead deals, preclinical PI3Kα lead.
1. Core Product / Service
Genesis was founded in 2019 as a spinout of Stanford's Pande lab. It renamed itself from Genesis Therapeutics to Genesis Molecular AI on 28 Oct 2025 [4]. Its GEMS platform is pitched as an "AI operating system for molecular design" that combines foundation models with physics [1]. In Oct 2025 it released Pearl, a protein–ligand co-folding model trained heavily on physics-generated synthetic data, which the company claims outperforms alphafold3 on its benchmarks [4]. Later releases include a distilled faster variant and an internal agentic discovery system (single-source).
The internal pipeline is entirely preclinical [1]:
- Lead: a pan-mutant PI3Kα allosteric inhibitor for breast and colorectal cancer, "approaching development candidate nomination".
- A cell-death (extrinsic apoptosis) programme.
- Several immunology small-molecule programmes.
Most revenue so far comes from partnerships. Upfront payments total $185M: Incyte $150M across two deals and Gilead $35M [1][2][3].
Wet lab. Genesis runs a "fully integrated laboratory" in San Diego; AI teams sit in the Bay Area and New York [1]. Job posts confirm in-house medicinal chemistry, computational chemistry, biology, DMPK and a CMC director role [9]. Lab size and address are not disclosed, and headcount is roughly 145–160 by third-party counts [8]. Chemistry postings refer to "industry collaborators" but name no CRO [9]. Under the 2026 Incyte expansion, Incyte shares proprietary experimental data with Genesis [2], so partner wet-lab output also feeds the models.
2. Target Users & Pain Points
- Pharma partners: Incyte (at least seven targets across two deals) and Gilead (three targets, with options). Earlier deals with Genentech and Eli Lilly (2022: $20M upfront, up to $670M) are no longer listed as active [1][3][8].
- Own pipeline: oncology and immunology targets that are hard to drug with standard medicinal chemistry.
- Pain addressed: structure-based design is limited by scarce experimental complex structures. Pearl's synthetic-data training is aimed at that gap.
3. Competitive Landscape
| Player | Approach | Vs. Genesis |
|---|---|---|
| isomorphic-labs | AlphaFold-lineage models, pharma deals plus own pipeline | Same structure-model-led strategy at larger scale |
| iambic-therapeutics | AI small molecules with weekly in-house design-make-test loops; clinical-stage | Further along clinically; heavier in-house automation |
| chai-discovery | Structure/design models sold to pharma | Pure model vendor; Genesis also owns assets |
| schrodinger | Physics + ML software plus pipeline | Incumbent physics stack that Genesis's models aim to replace |
4. Unique Observations
- Partner cash replaced venture rounds. Since the 2023 Series B there has been no priced venture round. Funding has come from pharma upfronts and strategic equity: undisclosed from NVIDIA, $40M from Incyte [1][2][7].
- The rename tracks the business. Moving from "Therapeutics" to "Molecular AI", and hiring a former Meta Llama lead as CTO [5], signals that the model is now the main product. That is consistent with partnership revenue far exceeding pipeline progress after seven years.
- Lab-in-the-loop by contract. Rather than scaling its own robotic lab, Genesis has written partner data-sharing into the Incyte deal [2], an alternative to the heavy in-house automation route.
5. Financials / Funding
- Seed ~$4M (2019, a16z; single source) [8]; Series A $52M (2020, led by Rock Springs Capital) [7].
- SAFE notes $23.9M (2022), converted into the Series B [7].
- Series B $200M new money (Aug 2023), co-led by a16z; NVentures, BlackRock, Fidelity and T. Rowe Price joined [6][7].
- NVIDIA strategic investment (Nov 2024, undisclosed) and $40M Incyte equity (May 2026) [2].
- Cumulative ≈ $300–340M. Third-party figure ~$296M before the Incyte equity; the company says "over $300M" [8]. Valuation is not disclosed.
6. People & Relationships
- Co-founder & CEO: Evan Feinberg (Stanford PhD, Pande lab).
- CTO: Sergey Edunov (joined Dec 2025; previously led Llama 2/3 research at Meta) [5]. Co-founder and former CTO Ben Sklaroff left in 2024 [8].
- CSO: Shifeng Pan (ex-Novartis GNF San Diego discovery chemistry; ex-Odyssey Therapeutics).
- Investors: a16z, Rock Springs, Menlo, Radical, nvidia (NVentures), Incyte. Partners: Incyte, Gilead.
Sources
- [1] Genesis Molecular AI, pipeline and partnerships page (2026-10-14)
- [2] Genesis Molecular AI, "Incyte and Genesis expand collaboration" (May 2026; accessed 2026-10-14)
- [3] Gilead, strategic collaboration with Genesis Therapeutics (Sept 2024; accessed 2026-10-14)
- [4] Business Wire, Pearl launch and company rename (2025-10-28; accessed 2026-10-14)
- [5] Business Wire, Sergey Edunov appointment (2025-12-02; accessed 2026-10-14)
- [6] BioPharma Dive, Genesis Series B (2026-10-14)
- [7] Genesis Therapeutics Form D (2023), SEC EDGAR (2026-10-14)
- [8] Contrary Research, Genesis Molecular AI profile (2026-10-14)
- [9] Genesis medicinal chemistry job posting (2026-10-14)